Share on LinkedInShare on LinkedIn

ARTICLE · 30 DECEMBER 2020

Drug Testing Legislation In 2020: A Look Back

Ogletree, Deakins, Nash, Smoak & Stewart
Explore more from Ogletree, Deakins, Nash, Smoak & Stewart

We would all be excused for wanting 2020 to disappear in a fog of medical marijuana.

United StatesCannabis & Hemp
Michael Clarkson
Michael Clarkson
Author LinkedIn connections

We would all be excused for wanting 2020 to disappear in a fog of medical marijuana. In case you missed it, here's a recap of a very busy year for Ogletree Deakins  Drug Testing Practice Group.

As we predicted in 2019, most of this year's action concerned medical and recreational marijuana. Not to be missed, however, there were important developments regarding accommodation of opiate addiction, pandemic-related drug testing guidance by the U.S. Department of Transportation (DOT), and even decriminalization of narcotics and psychedelic drugs. Here is a rundown of the highlights from 2020.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

See more popular content from

Article

The Intoxicating Hemp Products Ban Was Delayed A Month. Now What?

The House has passed a short-term funding bill postponing the federal ban on hemp-derived THC products from November 12th to December 11th. With comprehensive legislation unlikely before the new deadline and competing interests from cannabis sellers, alcohol producers, and state regulators creating policy gridlock, the future of intoxicating hemp products remains uncertain as midterm elections approach.
United StatesCannabis & Hemp
Harris Sliwoski
Harris Sliwoski
Article

IRC Section 280E And Cannabis Tax Planning: Recent Developments And Practical Considerations

The landscape surrounding Section 280E of the Internal Revenue Code continues to evolve with President Trump's Executive Order on medical marijuana rescheduling, advancing litigation in New Mexico Top Organics v. Commissioner, and shifting regulatory signals. Cannabis taxpayers face critical decisions about taking "non-280E" positions on their tax returns while the IRS maintains its enforcement stance and the U.S. Tax Court case addressing common arguments remains pending.
United StatesCannabis & Hemp
Foley Hoag LLP
Foley Hoag LLP